A Study of WU-CART-007 in People With T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Full Title

A Phase 2 Study of WU-CART-007 (soficabtagene geleucel), an Anti-CD7 Allogeneic CAR-T Cell Therapy, in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Kevin Curran’s office at 212-639-5836.